Navigation Links
2008 Open Enrollment for Medicare Part D Prescription Drug Coverage and Medicare Advantage Plans Begins Today
Date:11/15/2007

Campaign Features Major Outreach to Beneficiaries Eligible for Low Income Subsidies, Enhanced Publications and Online Tools

WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- The U.S. Department of Health and Human Services (HHS) announced that, beginning today, Medicare beneficiaries will be able to begin making enrollment changes in their health and prescription drug coverage for 2008, if necessary. The Medicare annual Open Enrollment Period for prescription drug plan runs from Nov. 15 through Dec. 31, 2007.

In addition, for Medicare Advantage (MA) plans only, beneficiaries can make one change in enrollment -- enrolling in a new plan, changing plans or canceling a plan -- between Jan. 1 and March 31, 2008.

"Now is the time for beneficiaries to prepare and compare their health and prescription drug coverage options and choose the plan that best meets their needs," HHS Secretary Mike Leavitt said. "We intend to keep building on the success the program has achieved thus far. The most recent satisfaction rate stands at 86 percent; the estimated average premium is 40 percent lower than originally estimated and total estimated costs are running $188 billion below initial projections. Part D is a program that is working well and is helping Medicare beneficiaries with their prescription drug costs."

HHS' Centers for Medicare and Medicaid Services (CMS) encourages all beneficiaries to act soon to compare their current plan with other plan options. If they are satisfied with their current plan, they do not need to do anything in order to maintain coverage. CMS wants eligible beneficiaries who do not have prescription drug coverage to know that, if they wait, they may pay a penalty on their premium.

Beneficiaries are encouraged to review their prescriptions and other health needs when assessing the plan options described in the "Medicare & You" handbook or on http://www.medicare.gov. In
'/>"/>

SOURCE U.S. Department of Health and Human Services
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Governor Rendell Announces CHIP Enrollment Clinics at Several Rite Aid Stores
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM)
4. New Online Tool Makes Enrollment in Blue Cross of California Easier
5. Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
6. My Medicare Matters(TM) Advises Evaluating Your Current Medicare Part D Plan During Open Enrollment
7. Northwestern University and ACORN Commence National Enrollment for Metastatic Breast Cancer Study
8. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
9. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
10. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
11. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 1Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 2Heska Announces Supply Agreement With Roche Diagnostics 6549 1Heska Announces Supply Agreement With Roche Diagnostics 6549 2Heska Announces Supply Agreement With Roche Diagnostics 6549 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 1Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 2Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 4